FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Equine veterinary journal2021; doi: 10.1111/evj.13489

Current joint therapy usage in equine practice: Changes in the last 10 years.

Abstract: Osteoarthritis is a common clinical condition in the performance horse. In the last 10 years, there has been substantial growth in understanding of the disease and in the development of novel therapies. Objective: To document changes in clinical use of joint therapies over the past 10 years. We also aimed to understand how newly developed therapies have been added to routine clinical practice. Methods: Survey of veterinary professionals. Methods: We administered an electronic survey to members of the American Association of the Equine Practitioners. Questions from a similar survey in 2009 were repeated and new questions were added. The responses were tabulated, analysed and compared to those of the previous survey. Results: A total of 407 completed surveys were returned. There were no significant differences between the current and previous surveys with respect to demographic parameters. Triamcinolone acetonide (TA) remained the most common corticosteroid used to treat high-motion joints. Methylprednisolone acetate (MPA) remained the most common corticosteroid to treat low-motion joints. The use of MPA for high-motion joints was significantly more common in 2009 than in 2019 (odds ratio [OR]: 2.38, 95% confidence interval [CI]: 1.66-3.42, P = .001). Biological therapies became more popular, and the likelihood of respondents reporting having used autologous conditioned serum was substantially higher in 2019 than in 2009 (OR: 4.24, 95% CI: 3.16-5.68, P < .001). Concomitant use of antibiotics with intra-articular medications became more common as well. Conclusions: This is a report of survey data and not directly measured treatments. Conclusions: There is a decrease in the use of MPA to treat high-motion joints. The use of biological therapies in joints has become more prevalent. There are clear differences in the use of joint therapies over time. While some differences agree with the scientific evidence, others are not fully concordant or are in direct conflict with the scientific literature.
© 2021 EVJ Ltd.
Get Full Text
Publication Date: 2021-06-18 PubMed ID: 34143532DOI: 10.1111/evj.13489Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study examines changes in the use of joint therapies for horses suffering from osteoarthritis over the past decade. It reveals a shift from using certain corticosteroids to the increased use of biological therapies.

Methods

  • The research was conducted through an electronic survey sent out to members of the American Association of Equine Practitioners.
  • The survey contained questions from a similar study conducted in 2009, and additional new questions relevant to the research.
  • The responses were gathered, analyzed, and compared to the responses from the 2009 survey.

Findings

  • The survey saw a total of 407 completed responses.
  • The data indicated that there were no significant changes between the current and previous surveys concerning demographic details.
  • Triamcinolone acetonide (TA) remained the most commonly administered corticosteroid to treat high-motion joints, such as knees and ankles.
  • Methylprednisolone acetate (MPA) continued to be the most frequently used corticosteroid for treating low-motion joints, including hocks and stifle joints.
  • Interestingly, the use of MPA for high-motion joints had significantly decreased in 2019, compared to 2009.
  • The study, however, noted an increase in the use of biological therapies for joint treatment. For instance, the use of autologous conditioned serum was substantially higher in 2019 than in 2009.
  • Alongside these shifts, there was also an increasing tendency for concomitant use of antibiotics with intra-articular medications.

Conclusions

  • The analysis is based on survey data rather than direct measurement of treatments.
  • There was a clear decline in the use of MPA to treat high-motion joints.
  • The use of biological therapies in joint treatment significantly increased over the past decade.
  • While these patterns generally conformed with existing scientific evidence, the researchers found some discrepancies, suggesting further investigation is needed to align practice with scientific literature.

Cite This Article

APA
Zanotto GM, Frisbie DD. (2021). Current joint therapy usage in equine practice: Changes in the last 10 years. Equine Vet J. https://doi.org/10.1111/evj.13489

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English

Researcher Affiliations

Zanotto, Gustavo M
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Frisbie, David D
  • Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.

Grant Funding

  • N/A / American Association of Equine Practitioners

References

This article includes 16 references
  1. Caron JP, Genovese RL. Principles and practices of joint disease treatment. In: Ross MW, Dyson SJ, editor. Diagnosis and Management of Lameness in the Horse. St. Louis, MO: Saunders, Elsevier; 2003:746-63.
  2. Frisbie DD. Synovial joint biology and pathobiology. In: Auer JA, Stick JA, editors. Equine surgery, St. Louis, MO: Saunders, Elsevier; 2006. p. 1036-54.
  3. Mcilwraith CW. Traumatic arthritis and posttraumatic osteoarthritis in the Horse. In: McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren R, editor. Joint disease in the horse. 2nd ed. St. Louis, MO: Elsevier; 2016: 33-48.
  4. McIlwraith CW. Licensed medications, ‘generic’ medications, compounding, and nutraceuticals - What has been scientifically validated, where do we encounter scientific mistruth, and where are we legally?. Proc Am Assoc Equine Prac 2004;50:1482.
  5. Frisbie DD. Principles of treatment of joint diseases. In: Auer JA, Stick JA, editors. Equine surgery, St. Louis, MO: Saunders, Elsevier; 2006. p. 1055-72.
  6. Ferris DJ, Frisbie DD, McIlwraith CW, Kawcak CE. Current joint therapy usage in equine practice: a survey of veterinarians 2009. Equine Vet J 2011;43(5):530-5.
    doi: 10.1111/j.2042-3306.2010.00324.xgoogle scholar: lookup
  7. McCluskey MJ, Kavenagh PB. Clinical use of triamcinolone acetonide in the horse (205 cases) and the incidence of glucocorticoid- induced laminitis associated with its use. Equine Vet Educ 2004;16:86-9.
    doi: 10.1111/j.2042-3292.2004.tb00272.xgoogle scholar: lookup
  8. Bathe AP. The corticosteroid laminitis story: 3. The clinician's viewpoint. Equine Vet J 2007;39(1):12-3.
    doi: 10.2746/042516407x165801google scholar: lookup
  9. Hammersley E, Duz M, Marshall J. Abstracts. Equine Vet J 2015;47:24.
    doi: 10.1111/evj.12486_54google scholar: lookup
  10. Chunekamrai S, Krook LP, Lust G, Maylin GA. Changes in articular cartilage after intra-articular injections of Methylprednisolone acetate in horses. Am J Vet 1989;50(10):1733-41.
  11. Frisbie DD, Kawcak CE, Baxter GM, Trotter GW, Powers BE, Lassen ED. Effects of 6a-methylpradnisolone acetate on an equine osteochondral fragment exercise model. Am J Vet Res 1998;59:1619-28.
  12. Steel CM, Pannirselvam RR, Anderson GA. Risk of septic arthritis after intra-articular medication: a study of 16,624 injections in Thoroughbred racehorses. Aust Vet J 2013;91(7):268-73.
    doi: 10.1111/avj.12073google scholar: lookup
  13. Smith LCR, Wylie CE, Palmer L, Ramzan PHL. Synovial sepsis is rare following intrasynovial medication in equine ambulatory practice. Equine Vet J 2019;51(5):595-9.
    doi: 10.1111/evj.13063google scholar: lookup
  14. Pezzanite L, Chow L, Soontararak S, Phillips J, Goodrich L, Dow S. Amikacin induces rapid dose-dependent apoptotic cell death in equine chondrocytes and synovial cells in vitro. Equine Vet J 2020;52(5):715-24.
    doi: 10.1111/evj.13243google scholar: lookup
  15. Maddox TW, Clegg PD, Williams NJ, Pinchbeck GL. Antimicrobial resistance in bacteria from horses: epidemiology of antimicrobial resistance. Equine Vet J 2015;47:756-65.
    doi: 10.1111/evj.12471google scholar: lookup
  16. Gustafson SB, McIlwraith CW, Jones RL, Dixon-White HE. Comparison of the effect of polysulfated glycosaminoglycan, corticosteroids, and sodium hyaluronate in the potentiation of a subinfective dose of Staphlococcus aureus in the midcarpal joint of horses. Am J VetRes 1989;50:2014-7.

Citations

This article has been cited 13 times.
  1. White GW. Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data. Open Vet J 2025 Sep;15(9):4007-4023.
    doi: 10.5455/OVJ.2025.v15.i9.6pubmed: 41200294google scholar: lookup
  2. Schultz RH, Hawkins JF, Hermida JA. Diagnostic imaging findings and management of osteoarthritis in pigs with image-guided intra-articular injections. Vet Surg 2025 Oct;54(7):1433-1442.
    doi: 10.1111/vsu.70002pubmed: 40873115google scholar: lookup
  3. Uldahl M, Mellor DJ. Regulatory Integrity and Welfare in Horse Sport: A Constructively Critical Perspective. Animals (Basel) 2025 Jun 30;15(13).
    doi: 10.3390/ani15131934pubmed: 40646833google scholar: lookup
  4. Roth SP, Liso G, Brehm W, Wagner B, Schnabel CL, Troillet A. Selected cytokine and chemokine concentrations in equine autologous conditioned serum are similar under defined and practically relevant storage conditions. Front Vet Sci 2025;12:1588240.
    doi: 10.3389/fvets.2025.1588240pubmed: 40496923google scholar: lookup
  5. Secor EJ, Womack SJ, Ysebaert MP, Colville MJ, Reesink HL. Synovial fluid alpha-2-macroglobulin, gelsolin and lubricin distinguish between osteoarthritic and healthy equine joints. Equine Vet J 2026 Jan;58(1):49-59.
    doi: 10.1111/evj.14511pubmed: 40342270google scholar: lookup
  6. Scheike AS, Plomp S, Fugazzola MC, Meurot C, Berenbaum F, van Weeren PR, Tryfonidou MA, von Hegedus JH. The Anti-Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models. J Orthop Res 2025 May;43(5):893-903.
    doi: 10.1002/jor.26050pubmed: 39904754google scholar: lookup
  7. Page AE, Johnson M, Parker JL, Jacob O, Poston R, Adams AA, Adam EN. The Effects of Intra-Articular Triamcinolone and Autologous Protein Solution on Metabolic Parameters in Horses. Animals (Basel) 2024 Aug 2;14(15).
    doi: 10.3390/ani14152250pubmed: 39123776google scholar: lookup
  8. Reis IL, Lopes B, Sousa P, Sousa AC, Caseiro AR, Mendonça CM, Santos JM, Atayde LM, Alvites RD, Maurício AC. Equine Musculoskeletal Pathologies: Clinical Approaches and Therapeutical Perspectives-A Review. Vet Sci 2024 Apr 26;11(5).
    doi: 10.3390/vetsci11050190pubmed: 38787162google scholar: lookup
  9. Della Tommasa S, Brehm W, Farì G, Bernetti A, Imperante A. Use of Autologous Conditioned Serum (ACS) for Osteoarthritis Treatment in Horses: A Systematic Review of Clinical Data. Vet Sci 2023 Dec 18;10(12).
    doi: 10.3390/vetsci10120707pubmed: 38133258google scholar: lookup
  10. O'Brien TJ, Hollinshead F, Goodrich LR. Extracellular vesicles in the treatment and prevention of osteoarthritis: can horses help us translate this therapy to humans?. Extracell Vesicles Circ Nucl Acids 2023 Jun;4(2):151-169.
    doi: 10.20517/evcna.2023.11pubmed: 37829144google scholar: lookup
  11. Skiöldebrand E, Adepu S, Lützelschwab C, Nyström S, Lindahl A, Abrahamsson-Aurell K, Hansson E. A randomized, triple-blinded controlled clinical study with a novel disease-modifying drug combination in equine lameness-associated osteoarthritis. Osteoarthr Cartil Open 2023 Sep;5(3):100381.
    doi: 10.1016/j.ocarto.2023.100381pubmed: 37416846google scholar: lookup
  12. Rockow M, Griffenhagen G, Landolt G, Hendrickson D, Pezzanite L. Current Antimicrobial Use in Horses Undergoing Exploratory Celiotomy: A Survey of Board-Certified Equine Specialists. Animals (Basel) 2023 Apr 22;13(9).
    doi: 10.3390/ani13091433pubmed: 37174470google scholar: lookup
  13. Zhao N, Curry D, Evans RE, Isguven S, Freeman T, Eisenbrey JR, Forsberg F, Gilbertie JM, Boorman S, Hilliard R, Dastgheyb SS, Machado P, Stanczak M, Harwood M, Chen AF, Parvizi J, Shapiro IM, Hickok NJ, Schaer TP. Microbubble cavitation restores Staphylococcus aureus antibiotic susceptibility in vitro and in a septic arthritis model. Commun Biol 2023 Apr 17;6(1):425.
    doi: 10.1038/s42003-023-04752-ypubmed: 37069337google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.